CardioSomaticsCardioSomatics2221-71852658-5707Eco-Vector8328510.17816/22217185.2021.3.201044Research ArticleAntithrombotic therapy and its impact on prognosis in patients with atrial fibrillation and myocardial infarction. Long-term observation resultsSolovevaMariia V.<p>Graduate Student</p>morethantea@rambler.ruhttps://orcid.org/0000-0002-3335-4986BolduevaSvetlana A.<p>D. Sci. (Med.), Prof.</p>morethantea@rambler.ruhttps://orcid.org/0000-0002-1898-084XMechnikov North-Western State Medical University281020211231581651710202117102021Copyright © 2021, Eco-Vector2021<p><strong><em>Aim. </em></strong>To study antithrombotic therapy (ATT) in patients with myocardial infarction (MI) type 1 and preexisting atrial fibrillation (AF), effect of ATT on prognosis.</p>
<p><strong><em>Material and methods. </em></strong>100 patients with type 1 MI and preexisting AF were selected. The exclusion criterion was severe concomitant pathology.</p>
<p><strong><em>Results. </em></strong>Only 13.0% of AF patients took anticoagulants (AC) adequately before hospitalization. 94.0% of patients in hospital and 80.5% at discharge were prescribed triple ATT at least for 1 month with transition to dual ATT (AC + disaggregant) for 12 months. ACs were prescribed in hospital in 100.0% of cases, at discharge in 93.1%. After 1 year 8.4% of patients stopped taking ACs, after 2.31.9 years 15.7%. The incidence of ischemic and hemorrhagic events didnt differ in patients with different regimens of ATT (double/triple) and types of AСs (vitamin K antagonists/non-vitamin K antagonist ACs). In the long-term period patients, who took ACs incorrectly or stopped taking ACs, had increased risks of stroke (OR 9.580; 95% CI 1.15379.599, <em>p</em>=0.0365); combined endpoint: recurrent MI + stroke + cardiovascular mortality (OR 2.556; 95% CI 1.1045.918,<em> p</em>=0.0284).</p>
<p><strong><em>С</em></strong><strong><em>onclusion.</em></strong> Patients with preexisting AF had a low adherence to ACs prior to MI. It increased after hospitalization and decreased during follow-up. In the long-term period patients, who took ACs incorrectly or stopped taking ACs, had significantly increased risks of stroke, combined endpoint. There were no differences in the prognosis depending on the type of ACs, the regimens of ATT administered in accordance with ischemic and hemorrhagic risks.</p>atrial fibrillationmyocardial infarctionantithrombotic therapyanticoagulantsprognosisadherence to anticoagulantsфибрилляция предсердийинфаркт миокардаантитромботическая терапияантикоагулянтыпрогнозприверженность приему антикоагулянтов[Болдуева С.А., Соловьева М.В., Облавацкий Д.В., и др. Инфаркт миокарда у больных с фибрилляцией предсердий. Кардиология. 2020;60(1):53-61 [Boldueva SA, Soloveva MV, Oblavatckii DV, et al. Myocardial infarction in the group of patients with atrial fibrillation. Kardiologiia. 2020;60(1):53-61 (in Russian)].DOI:10.18087/cardio.2020.1.n620][Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2013;174(1):107-14.DOI:10.1001/jamainternmed.2013.11912][Lopes RD, Pieper KS, Horton JR, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94:867-73.DOI:10.1136/hrt.2007.134486][Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:267-315. DOI:10.1093/eurheartj/ehv320][Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(38):119-77. DOI:10.1093/eurheartj/ehx393][Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med. 2010;123(9):785-9. DOI:10.1016/j.amjmed.2010.01.031][Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В. Тактика подбора антикоагулянтной терапии у пациентов с фибрилляцией предсердий и ишемической болезнью сердца. Кардиология. 2018;58(3):43-52 [Belenkov YuN, Shakaryants GA, Khabarova NV. Tactics of Selection of Anticoagulant Therapy in Patients With Atrial Fibrillation and Ischemic Heart Disease. Kardiologiia. 2018;58(3):43-52 (in Russian)].DOI:10.18087/cardio.2018.3.10098][Lee CJY, Pallisgaard JL, Bjerring JO, et al. Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;69(24):2901-9.DOI:10.1016/j.jacc.2017.04.033][Татаринцева З.Г., Космачева Е.Д., Кручинова С.В., и др. Антитромбоцитарная терапия у пациентов с фибрилляцией предсердий на фоне острого коронарного синдрома в реальной клинической практике (по данным тотального регистра острого коронарного синдрома по Краснодарскому краю). Кардиология: новости, мнения, обучение. 2018;6(4):6-13 [Tatarintseva ZG, Kosmacheva ED, Kruchinova SV, et al. Antiplatelet therapy in patients with atrial fibrillation on the background of acute coronary syndrome in real clinical practice according to the total register of acute coronary syndrome in the Krasnodar Territory. Cardiology: News, Opinions, Training. 2018;6(4):6-13 (in Russian)].DOI:10.24411/2309-1908-2018-14001][Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol. 2019;26(13):1373-82. DOI:10.1177/2047487319841940][Collet JP, Thiele Н, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020;ehaa575.DOI:10.1093/eurheartj/ehaa575][Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612][Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015;66(6):616-27.DOI:10.1016/j.jacc.2015.05.062][Lopes RD, Hong H, Harskamp RE, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol. 2020;5(5):582-9. DOI:10.1001/jamacardio.2019.6175][Batra G, Friberg L, Erlinge D, et al. Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):36-45. DOI:10.1093/ehjcvp/pvx033][Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981-9.DOI:10.1016/j.jacc.2013.05.029]